|
1
|
Cao SM, Simons MJ and Qian CN: The
prevalence and prevention of nasopharyngeal carcinoma in China.
Chin J Cancer. 30:114–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coghill AE and Hildesheim A: Epstein-Barr
virus antibodies and the risk of associated malignancies: Review of
the literature. Am J Epidemiol. 180:687–695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stoker SD, van Diessen JN, de Boer JP,
Karakullukcu B, Leemans CR and Tan IB: Current treatment options
for local residual nasopharyngeal carcinoma. Curr Treat Options
Oncol. 14:475–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He ML, Luo MX, Lin MC and Kung HF:
MicroRNAs: Potential diagnostic markers and therapeutic targets for
EBV-associated nasopharyngeal carcinoma. Biochim Biophys Acta.
1825:1–10. 2012.PubMed/NCBI
|
|
5
|
Liu N, Tang LL, Sun Y, Cui RX, Wang HY,
Huang BJ, He QM, Jiang W and Ma J: MiR-29c suppresses invasion and
metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer
Lett. 329:181–188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan JK, Tan EL and Gan SY: Elucidating the
roles of miR-372 in cell proliferation and apoptosis of
nasopharyngeal carcinoma TW01 cells. Exp Oncol. 36:170–173.
2014.PubMed/NCBI
|
|
7
|
Zhang ZC, Li YY, Wang HY, Fu S, Wang XP,
Zeng MS, Zeng YX and Shao JY: Knockdown of miR-214 promotes
apoptosis and inhibits cell proliferation in nasopharyngeal
carcinoma. PLoS One. 9:e861492014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wong TS, Man OY, Tsang CM, Tsao SW, Tsang
RK, Chan JY, Ho WK, Wei WI and To VS: MicroRNA let-7 suppresses
nasopharyngeal carcinoma cells proliferation through downregulating
c-Myc expression. J Cancer Res Clin Oncol. 137:415–422. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nohata N, Hanazawa T, Enokida H and Seki
N: MicroRNA-1/133a and microRNA-206/133b clusters: Dysregulation
and functional roles in human cancers. Oncotarget. 3:9–21. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao Y, Huang J, Zhang L, Qu Y, Li J, Yu
B, Yan M, Yu Y, Liu B and Zhu Z: MiR-133b is frequently decreased
in gastric cancer and its overexpression reduces the metastatic
potential of gastric cancer cells. BMC Cancer. 14:342014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wen D, Li S, Ji F, Cao H, Jiang W, Zhu J
and Fang X: MiR-133b acts as a tumor suppressor and negatively
regulates FGFR1 in gastric cancer. Tumour Biol. 34:793–803. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiang KM and Li XR: MiR-133b acts as a
tumor suppressor and negatively regulates TBPL1 in colorectal
cancer cells. Asian Pac J Cancer Prev. 15:3767–3772. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao H, Li M, Li L, Yang X, Lan G and
Zhang Y: MiR-133b is down-regulated in human osteosarcoma and
inhibits osteosarcoma cells proliferation, migration and invasion
and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang C, Yao C, Li H, Wang G and He X:
Serum levels of microRNA-133b and microRNA-206 expression predict
prognosis in patients with osteosarcoma. Int J Clin Exp Pathol.
7:4194–4203. 2014.PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Priceman SJ, Shen S, Wang L, Deng J, Yue
C, Kujawski M and Yu H: S1PR1 is crucial for accumulation of
regulatory T cells in tumors via STAT3. Cell Rep. 6:992–999. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Niederwieser C, Kohlschmidt J, Volinia S,
Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser
D, Becker H, et al: Prognostic and biologic significance of DNMT3B
expression in older patients with cytogenetically normal primary
acute myeloid leukemia. Leukemia. 29:567–575. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang
Z, Zhu W, Shu Y and Liu P: MiR-145, miR-133a and miR-133b inhibit
proliferation, migration, invasion and cell cycle progression via
targeting transcription factor Sp1 in gastric cancer. FEBS Lett.
588:1168–1177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu L, Shao X, Gao W, Zhang Z, Liu P, Wang
R, Huang P, Yin Y and Shu Y: MicroRNA-133b inhibits the growth of
non-small-cell lung cancer by targeting the epidermal growth factor
receptor. FEBS J. 279:3800–3812. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin
C and Zhang W: MicroRNA-133 inhibits cell proliferation, migration
and invasion in prostate cancer cells by targeting the epidermal
growth factor receptor. Oncol Rep. 27:1967–1975. 2012.PubMed/NCBI
|
|
21
|
Liang J, Nagahashi M, Kim EY, Harikumar
KB, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM, Avni D, et
al: Sphingosine-1-phosphate links persistent STAT3 activation,
chronic intestinal inflammation, and development of
colitis-associated cancer. Cancer Cell. 23:107–120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Deng J, Liu Y, Lee H, Herrmann A, Zhang W,
Zhang C, Shen S, Priceman SJ, Kujawski M, Pal SK, et al:
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at
future metastatic sites. Cancer Cell. 21:642–654. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee H, Deng J, Kujawski M, Yang C, Liu Y,
Herrmann A, Kortylewski M, Horne D, Somlo G, Forman S, et al:
STAT3-induced S1PR1 expression is crucial for persistent STAT3
activation in tumors. Nat Med. 16:1421–1428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
